ArticleEndocrine2026
Molecular diagnosis of maturity-onset diabetes of the young via whole-exome sequencing: a cohort study in Taizhou, China.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundMaturity-onset diabetes of the young (MODY) is a monogenic disease that is often undiagnosed or misdiagnosed in China, leading to inappropriate therapy. In this study, we aimed to determine the pathogenic variants in Chinese patients with clinically suspected MODY.
methodsA total of 20 probands from 20 unrelated families with suspected MODY in Taizhou Hospital affiliated to Wenzhou Medical University from 2019 to 2023 were enrolled. Whole-exome sequencing (WES) and WES-based copy number variant (CNV) detection were performed for mutational analysis, and the genotype and phenotype of these affected patients were analyzed.
resultsIn this cohort, there were 12 males (60.0%) and 8 females (40.0%) with a mean age of 16.2 ± 5.9 years (range 4.8–27.0 years) and a mean age of diabetes diagnosis of 14.9 ± 5.6 years (range 4.0–24.0 years). Among these patients, 13 patients experienced polyuria, polydipsia or weight loss, and 8 patients showed additional features such as hyperuricemia, uterine malformation and renal cysts. Genetic analysis identified 5 pathogenic mutations of 2 MODY genes in 5 families, accounting for 25% of potential families. Three patients (15.0%, 3/20) harbored HNF1A variants, while two cases (10.0%, 2/20) carried whole HNF1B deletion. No significant difference in clinical characteristics except for fasting insulin levels were found between MODY patients and non-MODY patients. Following an accurate genetic diagnosis, two probands with MODY3 and their affected parents achieved good glycemic control after switching to sulfonylureas.
conclusionUsing the WES technology, pathogenic variants in the HNF1A and HNF1B genes were detected in 5 (25.0%) families of the Taizhou cohort in China. Our study underscores the importance of precise molecular diagnosis for optimal treatment and management of patients and helps to enhance the clinicians’ awareness of the disease and reduce the misdiagnosis of MODY.
Indexed as
Identifiers
41801597What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.